Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis
Interventions: Rituximab, Methotrexate, Methylprednisolone, Folic Acid; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 21 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 42
States / cities: Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 36 more

Conditions: Graft Versus Host Disease
Interventions: Daclizumab, methylprednisolone, Placebo; Biological · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 8
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Buffalo, New York + 3 more

Conditions: Myasthenia Gravis
Interventions: Hematopoietic Stem Cell Transplantation, Cyclophosphamide, ATG (rabbit), Mesna, Methylprednisolone, G-CSF; Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 15 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: IgA Nephropathy (IgAN)
Interventions: Avacopan, Prednisone, Methylprednisolone (drug), Prednisolone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Cataracts
Interventions: Xibrom, and Optive, Xibrom and Pred Forte; Drug
Lead sponsor: Bp Consulting, Inc; Network
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Tarpon Springs, Florida

Conditions: Eye Infections, Postoperative Complications
Interventions: Prednisolone and Tobramycin, Prednisolone; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: Great Bend, Kansas • Boston, Massachusetts • Saint Joseph, Michigan + 3 more

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Steroid arm, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Renal Transplantation
Interventions: Alemtuzumab, rabbit antithymocyte globulin, Belatacept, Tacrolimus, Mycophenolate mofetil, early cessation of steroids; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more

Conditions: End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis, Renal Replacement Therapy, Renal Transplantation
Interventions: Induction therapy, Corticosteroids, EVR+rCNI, MPA+sCNI; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,037 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 40
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 32 more

Conditions: Post-operative Pain, Quadriceps Muscle Strength
Interventions: Adductor Canal Block, Femoral Nerve Block, Ultrasound, Stimuplex A needle, local anaesthetic injection, Steroid Drug; Procedure · Device · Drug
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 8 Years to 18 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Gout
Interventions: Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis, Infusion Reaction (IR) Prophylaxis, Folic Acid; Biological · Drug · Dietary Supplement
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 3 more

Conditions: Cataracts, Corneal Edema, Retinal Structural Change, Deposit and Degeneration, Visual Acuity Reduced Transiently
Interventions: Difluprednate ophthalmic emulsion 0.05%, Prednisolone acetate 1%; Drug
Lead sponsor: Edward J. Holland; Other
Eligibility: 21 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Edgewood, Kentucky • Lynbrook, New York • Mt. Pleasant, South Carolina

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Vincristine, Dexamethasone, Inotuzumab Ozogamicin, Methotrexate, Cytarabine, Methylprednisolone, Rituximab, Prednisone, Mercaptopurine, Doxorubicin; Drug · Biological
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 50 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 71
States / cities: Birmingham, Alabama • Irvine, California • Orange, California + 60 more

Conditions: Kidney Transplantation, Renal Transplant Recipients
Interventions: Lulizumab, Tacrolimus, Thymoglobulin®, Methylprednisolone, Mycophenolate Mofetil, Prednisone; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Interventions: Azacitidine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Hydrocortisone Sodium Succinate, Leucovorin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Thioguanine, Vincristine, Vincristine Sulfate; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 364 Days
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 157
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 128 more

Conditions: Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Up to 54 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: COPD
Interventions: Low Dose Corticosteroids, High Dose Corticosteroids; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 40 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 2
States / cities: New Brunswick, New Jersey • Plainsboro, New Jersey

Conditions: Post-surgical Cystoid Macular Edema (PSCME)
Interventions: PredA + Kelac; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiogenic Shock, Heart Failure, Inflammation
Interventions: Methylprednisone, Standard of Care (SOC); Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Leukemia, Acute Lymphoblastic Leukemia
Interventions: Rituximab, Cyclophosphamide (CTX), Doxorubicin, Vincristine, Dexamethasone, Methotrexate (MTX), Cytarabine, G-CSF, Mesna, Pegylated asparaginase, Pegfilgrastim, Solumedrol; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions: Bleomycin Sulfate, Brentuximab Vedotin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Methylprednisolone, Pharmacological Study, Prednisone, Quality-of-Life Assessment, Questionnaire Administration, Vincristine Sulfate; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 22 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 182
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 140 more

Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition
Interventions: filgrastim, cyclosporine, methylprednisolone, prednisone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 10 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
Interventions: Obinutuzumab, Venetoclax, Magrolimab, Acetaminophen, Diphenhydramine, Prednisone/prednisolone, Methylprednisolone, CT Scan chest/abdomen/pelvis, MRI, 18-FDG-PET, Bone Marrow Biopsy, Bone Marrow Aspiration; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, melphalan, methylprednisolone, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Up to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Search by objective public record fields.

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

Comparing Optical Coherence Tomography (OCT) and Visual Acuity Outcomes in Subjects Undergoing Cataract Surgery, Who Receive Xibrom Ophthalmic Solution and Standard Presurgical Care vs. Xibrom Ophthalmic Solution Plus Prednisolone Acetate 1% and Standard Presurgical Care

A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte

Steroid Treatment for Sickle Cell Pain Crisis

Belatacept Early Steroid Withdrawal Trial

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

Ultrasound Guided Adductor Canal Versus Femoral Nerve Blocks for Anterior Cruciate Ligament Reconstruction in Pediatrics

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.

Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia

Selective CD28 Blockade in Renal Transplant Recipients

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Dose of Corticosteroids in COPD

Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)

CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases